FDA approved Ionis’ Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
Where Today's News Shapes Tomorrow
